Free Trial
OTCMKTS:EMBI

Emerald Bioscience (EMBI) Stock Price, News & Analysis

Emerald Bioscience logo

About Emerald Bioscience Stock (OTCMKTS:EMBI)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
6.96 million shs
Average Volume
14.24 million shs
Market Capitalization
$24.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Emerald Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus. The company was formerly known as Nemus Bioscience, Inc. and changed its name to Emerald Bioscience, Inc. in March 2019. Emerald Bioscience, Inc. was founded in 2012 and is based in San Diego, California.

Remove Ads
Receive EMBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emerald Bioscience and its competitors with MarketBeat's FREE daily newsletter.

EMBI Stock News Headlines

PIMCO Emerging Markets Bond Instl
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Sprint Bioscience AB SPRINT
Daré Bioscience, Inc. (DARE)
See More Headlines

EMBI Stock Analysis - Frequently Asked Questions

Shares of EMBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Emerald Bioscience investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Gold Resource (GORO), Meta Platforms (META), Processa Pharmaceuticals (PCSA), Akero Therapeutics (AKRO) and CymaBay Therapeutics (CBAY).

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
N/A
Sub-Industry
N/A
Current Symbol
OTCMKTS:EMBI
CIK
N/A
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$1.05 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$24.13 million
Optionable
Not Optionable
Beta
0.43
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (OTCMKTS:EMBI) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners